Lilly Oncology is dedicated to delivering innovative treatment approaches with the goal of improving the outcomes of people living with cancer. We are driven to accelerate the pace and progress of cancer care by developing a broad portfolio of therapies, including those tailored to unique patients and those that modulate the immune system. Lilly's commitment to improving the length and quality of people's lives is achieved through its internal drug development programs and its support of Investigator Initiated Research. Lilly Oncology focuses its drug development programs in three key areas: cell signaling, tumor microenvironment and immuno-oncology.

  • Cell Signaling
  • Immuno-Oncology
  • Microenvironment